# NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

> **NCT04484909** · PHASE1 · SUSPENDED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Borderline Resectable Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8

## Interventions

- **OTHER:** Hafnium Oxide-containing Nanoparticles NBTXR3
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04484909
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-07-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** PI Request
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484909, "NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04484909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*